Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Expert Opin Biol Ther. 2010 Mar;10(3):451-8. doi: 10.1517/14712591003596318.
A significant number of patients relapse or do not respond to rituximab due to intrinsic or acquired resistance. Hence, mAbs targeting other cell surface antigens on B-cell lymphomas are being studied. CD80 is a glycoprotein expressed on Hodgkin's lymphoma, mature B-cell lymphomas and immunoeffector cells which may have T-regulatory, in addition to direct antitumor activity. CD80 serves as an attractive target in the continued development of mAbs against lymphoma.
Preclinical studies with galiximab, an anti-CD80 primatized mAb, have been encouraging and have demonstrated antitumor activity against various B-cell lymphoma models, both as a single agent as well as in combination with rituximab. Data were reviewed from a PubMed literature search from 1975 to 2009 and also included a review of abstracts from published proceedings of annual meetings from the American Society of Hematology and International Conference of Malignant Lymphoma, Lugano.
Readers will gain a better understanding of mechanisms of action (both documented and proposed) of galiximab. An update of currently available clinical data will be presented.
Data from completed clinical trials are promising and galiximab is being studied in both upfront and relapsed settings with the potential of being incorporated into the future treatment of B-cell lymphoma.
由于内在或获得性耐药，相当数量的患者复发或对利妥昔单抗无反应。因此，正在研究针对 B 细胞淋巴瘤其他细胞表面抗原的 mAbs。CD80 是一种糖蛋白，表达于霍奇金淋巴瘤、成熟 B 细胞淋巴瘤和免疫效应细胞，除了直接抗肿瘤活性外，还可能具有 T 调节活性。CD80 是继续开发针对淋巴瘤的 mAbs 的有吸引力的靶标。
抗 CD80 单克隆抗体 galiximab 的临床前研究令人鼓舞，并证明了对各种 B 细胞淋巴瘤模型的抗肿瘤活性，无论是作为单一药物还是与利妥昔单抗联合使用。数据来自 1975 年至 2009 年的 PubMed 文献检索，还包括对美国血液学会和卢加诺恶性淋巴瘤国际会议出版会议摘要的回顾。
读者将更好地了解 galiximab 的作用机制（包括已记录和提出的机制）。将介绍当前可用的临床数据的最新情况。
已完成的临床试验数据很有希望，galiximab 正在进行初治和复发患者的研究，有可能被纳入未来 B 细胞淋巴瘤的治疗方案。
